This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Keryx Releases Auryxia Data for Iron Deficiency Anemia
by Zacks Equity Research
Keryx Biopharmaceuticals, Inc. (KERX) recently announced the publication of results from a phase III in the online issue of the Journal of the American Society of Nephrology (JASN).
Novartis to Conduct Trial on Obese, Type II Diabetes Patients
by Zacks Equity Research
In a recent announcement, MorphoSys AG mentioned that its partner Swiss major Novartis AG (NVS) will conduct a phase II clinical trial on pipeline candidate bimagrumab in obese patients with type II diabetes.
TESARO Varubi IV Gets Complete Response Letter in the U.S.
by Zacks Equity Research
TESARO (TSRO) announced that it has received a Complete Response Letter from the FDA regarding its NDA for Varubi IV.
Pluristem (PSTI) Intermittent Claudication Study Enrolled
by Zacks Equity Research
Pluristem Therapeutics (PSTI) has completed patient enrollment in a phase II study on PLX-PAD cells for the treatment of intermittent claudication.
TherapeuticsMD's Rejoice Study Data Published in Journal
by Zacks Equity Research
TherapeuticsMD, Inc. (TXMD) announced the publication of two manuscripts detailing with the results of the company's pivotal phase III study (Rejoice) in Menopause: The Journal of The North American Menopause Society.
Lilly, Merck Expand Tie-Up to Study Lartruvo-Keytruda Combo
by Zacks Equity Research
Eli Lilly and Company (LLY) and Merck & Co., Inc. (MRK) expanded their existing immuno-oncology partnership to include a new study that will evaluate Lilly???s Lartruvo in combination with Merck???s Keytruda in patients with STS.
Gilead (GILD) HBV Drug Vemlidy Receives European Approval
by Zacks Equity Research
Gilead Sciences (GILD) gained EU approval for Vemlidy for the treatment of chronic HBV infection.
Alexion (ALXN) Files for Label Expansion of Soliris in U.S., EU
by Zacks Equity Research
Alexion (ALXN) has filed regulatory applications in both the U.S. and EU for Soliris for the treatment of patients with refractory generalized myasthenia gravis.
Amgen: Phase III Data on Hyperparathyroidism Drug Published
by Zacks Equity Research
Amgen Inc. (AMGN) announced that data from three phase III studies on its pipeline candidate, Parsabiv (etelcalcetide), were published in the Journal of the American Medical Association (JAMA).
Sanofi, ImmuNext Ink Deal, Focus on Autoimmune Diseases
by Zacks Equity Research
Sanofi (SNY) announced an agreement with ImmuNext, Inc. for the development of a novel antibody to treat a range of autoimmune diseases including lupus and multiple sclerosis.
Kite Pharma Inks Deals for CAR T Cell Drug in Japan, China
by Zacks Equity Research
Kite Pharma (KITE) announced that it has entered into a strategic partnership with Daiichi Sankyo to develop and commercialize axicabtagene ciloleucel (KTE-C19) in Japan.
Emergent Down on '17 View, Posts Preliminary '16 Results
by Zacks Equity Research
Emergent announced better-than-expected preliminary 2016 results. However, the outlook for 2017 fell short of estimates.
4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal
by Arpita Dutt
Takeda to Buy ARIAD, More M&As to Follow in Biotech Sector?
Incyte/Merck to Start More Epacadostat-Keytruda Studies
by Zacks Equity Research
Incyte (INCY) and Merck (MRK) announced that they have decided to initiate additional pivotal studies on epacadostat, in combination with Merck's Keytruda.
AMAG, Palatin Ink Deal to Focus on Female Sexual Disorder
by Zacks Equity Research
AMAG (AMAG) announced that it has entered into an agreement with Palatin (PTN) for the exclusive U.S. rights to develop and commercialize Rekynda.
AbbVie's HCV Combo Favorable in Japanese Phase III Study
by Zacks Equity Research
AbbVie Inc. (ABBV) announced positive top-line data from a phase III study on its pan-genotypic ribavirin (RBV)-free regimen of glecaprevir/pibrentasvir (G/P) in Japanese patients.
ARIAD Pharma Stock Gains on Acquisition Deal with Takeda
by Zacks Equity Research
ARIAD Pharmaceuticals, Inc.'s (ARIA) shares surged 72.8% after the company announced a definitive agreement to be acquired by Japan-based Takeda Pharmaceutical Company Limited (TKPYY) for approximately $5.2 billion.
Kite Pharma (KITE) to Move Cancer Candidate into Phase I
by Zacks Equity Research
Kite Pharma, Inc. (KITE) announced that it has filed a Investigational New Drug (IND) application with the FDA to initiate phase I studies on KITE-718, a TCR candidate targeting MAGE in a solid tumor.
Kite Pharma Enters into Partnership with Vitruvian Networks
by Zacks Equity Research
Kite Pharma (KITE) entered into a strategic partnership with Vitruvian Networks to create a software solution to support commercial availability of T-cell therapies.
Kite Pharma Begins Filing for KTE-C19, Presents Data at ASH
by Zacks Equity Research
Kite Pharma, Inc. (KITE) announced it has initiated a rolling submission of the Biologic License Application (BLA) for its lead pipeline candidate, KTE-C19, to the FDA.